BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pandya DN, Bhatt NB, Almaguel F, Rideout-Danner S, Gage HD, Solingapuram Sai KK, Wadas TJ. 89Zr-Chloride Can Be Used for Immuno-PET Radiochemistry Without Loss of Antigen Reactivity In Vivo. J Nucl Med 2019;60:696-701. [PMID: 30442753 DOI: 10.2967/jnumed.118.216457] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Privé BM, Derks YHW, Rosar F, Franssen GM, Peters SMB, Khreish F, Bartholomä M, Maus S, Gotthardt M, Laverman P, Konijnenberg MW, Ezziddin S, Nagarajah J, Heskamp S. 89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man. Eur J Nucl Med Mol Imaging 2021. [PMID: 34932154 DOI: 10.1007/s00259-021-05661-0] [Reference Citation Analysis]
2 Chomet M, van Dongen GAMS, Vugts DJ. State of the Art in Radiolabeling of Antibodies with Common and Uncommon Radiometals for Preclinical and Clinical Immuno-PET. Bioconjug Chem 2021;32:1315-30. [PMID: 33974403 DOI: 10.1021/acs.bioconjchem.1c00136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Pandya DN, Henry KE, Day CS, Graves SA, Nagle VL, Dilling TR, Sinha A, Ehrmann BM, Bhatt NB, Menda Y, Lewis JS, Wadas TJ. Polyazamacrocycle Ligands Facilitate 89Zr Radiochemistry and Yield 89Zr Complexes with Remarkable Stability. Inorg Chem 2020;59:17473-87. [PMID: 33169605 DOI: 10.1021/acs.inorgchem.0c02722] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Lecoq P, Morel C, Prior JO, Visvikis D, Gundacker S, Auffray E, Križan P, Turtos RM, Thers D, Charbon E, Varela J, de La Taille C, Rivetti A, Breton D, Pratte JF, Nuyts J, Surti S, Vandenberghe S, Marsden P, Parodi K, Benlloch JM, Benoit M. Roadmap toward the 10 ps time-of-flight PET challenge. Phys Med Biol 2020;65:21RM01. [PMID: 32434156 DOI: 10.1088/1361-6560/ab9500] [Cited by in Crossref: 38] [Cited by in F6Publishing: 49] [Article Influence: 19.0] [Reference Citation Analysis]
5 Chomet M, Schreurs M, Bolijn MJ, Verlaan M, Beaino W, Brown K, Poot AJ, Windhorst AD, Gill H, Marik J, Williams S, Cowell J, Gasser G, Mindt TL, van Dongen GAMS, Vugts DJ. Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical 89Zr-immuno-PET. Eur J Nucl Med Mol Imaging 2021;48:694-707. [PMID: 32889615 DOI: 10.1007/s00259-020-05002-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
6 Pandya DN, Sinha A, Yuan H, Mutkus L, Stumpf K, Marini FC, Wadas TJ. Imaging of Fibroblast Activation Protein Alpha Expression in a Preclinical Mouse Model of Glioma Using Positron Emission Tomography. Molecules 2020;25:E3672. [PMID: 32806623 DOI: 10.3390/molecules25163672] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
7 Wei W, Rosenkrans ZT, Liu J, Huang G, Luo QY, Cai W. ImmunoPET: Concept, Design, and Applications. Chem Rev 2020;120:3787-851. [PMID: 32202104 DOI: 10.1021/acs.chemrev.9b00738] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 28.5] [Reference Citation Analysis]